Non-Idiopathic Scoliosis Treated With Tranexamic Acid
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01089140|
Recruitment Status : Terminated (Inadequate number of potential participants)
First Posted : March 18, 2010
Last Update Posted : July 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|Non-idiopathic Scoliosis||Drug: Tranexamic acid 10mg/kg/hr Drug: Tranexamic acid 100 mg/kg/h infusion Drug: Saline solution||Phase 2|
To investigate whether tranexamic acid (TXA) reduces perioperative blood loss and transfusion requirement in pediatric patients with secondary scoliosis undergoing posterior spinal fusion.In addition determination of the optimal TXA dosing for perioperative reduction of blood loss and transfusion requirement as well as to evaluate use of thromboelastography (TEG) as a measure of coagulation and fibrinolysis in pediatric patients with secondary scoliosis undergoing posterior spinal fusion (this may help guide blood product therapy).
The investigation will determine the effects of TXA on the TEG profile and whether plasminogen activator inhibitor-1 (PAI-1) level affects bleeding and transfusion requirement during scoliosis surgery. Finally to investigate whether PAI-1 level affects bleeding in response to TXA during scoliosis surgery.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Blood Loss and Transfusion Requirement in Pediatric Patients With Non-Idiopathic Scoliosis Treated With Tranexamic Acid Undergoing Posterior Spinal Instrumentation and Fusion.|
|Actual Study Start Date :||November 2014|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
|Experimental: . Tranexamic acid low dose 10 mg/kg||
Drug: Tranexamic acid 10mg/kg/hr
Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
Other Name: TXA
|Experimental: Tranexamic acid 100mg/kg||
Drug: Tranexamic acid 100 mg/kg/h infusion
Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
Other Name: TXA
|Placebo Comparator: Saline Placebo||
Drug: Saline solution
- Perioperative blood loss and transfusion requirement [ Time Frame: 8 hours ]
- Thromboelastography (TEG): TEG monitors coagulation of blood samples in vitro to produce a complete picture of clot formation, strength and dissolution (i.e. fibrinolysis). [ Time Frame: After Induction- Prior to Drug Administration, Immediately after Bolus Dose ]
- Plasminogen Activator Inhibitor-1 [ Time Frame: Baseline -Immediately after induction and prior to administration of study drug ]Different genotypes for the plasminogen activator inhibitor-1 (PAI-1) gene may have varying degrees of bleeding. PAI-1 inhibits the transformation of plasminogen to plasmin thereby decreasing plasmin-induced fibrinolysis. Thus, PAI-1 promotes clot stability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01089140
|Hospital for Sick Children|
|Toronto, Ontario, Canada|
|Principal Investigator:||Tara Der, M.sc. MD.,(FRCPC)||Hospital for SickkIds|